Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Hyun-Jin Nam, Seock-Ah Im, Young-Kwang Yoon, Tae-You Kim, Sae-Won Han, Hwang-Phill Kim, Paul Elvin, Yung-Jue Bang, Ahrum Min, Do-Youn Oh, Sang-Hyun Song
Publikováno v:
Molecular Cancer Therapeutics. 12:16-26
Src is a nonreceptor tyrosine kinase involved in the cross-talk and mediation of many signaling pathways that promote cell proliferation, adhesion, invasion, migration, and tumorigenesis. Increased Src activity has been reported in many types of huma
Autor:
Luiza Madia Lourenco, Fiona Cahill, Sivan M. Bokobza, Yanyan Jiang, Anika M. Weber, Nuramalina H. Mumin, Thomas M. Ashton, Aoife M. Devery, Anderson J. Ryan, Neele Drobnitzky
Publikováno v:
Molecular Cancer Therapeutics. 14:C114-C114
Lung cancer is the leading cause of cancer related death worldwide and adenocarcinoma is the most prevalent subtype. LKB1 (STK11) is the second most commonly altered tumour suppressor in adenocarcinoma and is inactivated in 17% of samples (1). LKB1 i
Autor:
Esra A. Akbay, Margaret Soucheray, Fatima Al-Shahrour, Jeffrey H. Becker, Ines Pulido, Kwok-Kin Wong, Neil Johnson, Eiki Kikuchi, Camilla L. Christensen, Wei Qiu, Michael P. Kahle, Julian Carretero, Takeshi Shimamura
Publikováno v:
Molecular Cancer Therapeutics. 14:C75-C75
The purpose of our study was to define a method and mechanism for overcoming the resistance of clinically relevant KRAS-mutant/LKB1-deficient NSCLC cells to the BET-bromodomain inhibitor JQ1. LKB1 (Serine/threonine kinase 11) is mutated with loss of
Autor:
Wilma Pastori, Simona Bindi, Daniele Casero, Marina Ciomei, Sabrina Cribioli, Nadia Amboldi, Cinzia Pellizzoni, Paola Gnocchi, Nilla Avanzi, Daniele Donati, Elena Ardini, Giulia Canevari, Gemma Texido, Arturo Galvani, Marcella Nesi, Maria Gabriella Brasca, Eduard R. Felder, Antonella Isacchi, Cinzia Cristiani, Roberta Ceruti, Veronica Patton
Publikováno v:
Molecular Cancer Therapeutics. 14:A179-A179
The Janus Kinases (JAK1, JAK2, JAK3, TYK2) are non-receptor tyrosine kinases that play important roles in hematopoiesis and immune response. In particular, gene ablation of JAK1 or JAK2 in the mouse is incompatible with life, due to neurological defe
Autor:
Sandeep Gupta, Vaibhav Sihorkar, Sanjeeva Reddy, Mahaboobi Jaleel, Vijay Kumar Nyavanandi, Niranjan Rao, Murali Ramachandra, Hosahalli Subramanya, Roger Smith, Scott K. Thompson, Aravind Basavaraju
Publikováno v:
Molecular Cancer Therapeutics. 14:B100-B100
Various genes in RAS-RAF and PI3K pathways are frequently mutated in a wide variety of solid tumors. Concurrent double mutations are also observed quite often in a broad range of tumor types. Combined inhibition of both pathways has been shown to imp
Publikováno v:
Molecular Cancer Therapeutics. 14:C65-C65
Background: Gene fusions involving members of the NTRK family have been identified in several types of cancer. The use of TRK inhibitors in vitro and in vivo have demonstrated activity against a number of different NTRK fusions in different tumor typ
Autor:
David Anthony Barda, Xueqian Gong, Youyan Zhang, Xiang S. Ye, Robert D. Van Horn, Chunping Yu, Tinggui Yin, Xiaoyi Zhang, Sean Buchanan, Sheng-Bin Peng, William T. McMillen
Publikováno v:
Molecular Cancer Therapeutics. 12:B229-B229
TANK-binding kinase 1 (TBK1) is a non-canonical IKK family member and plays a critical role in innate immunity by modulating cytokine production, interferon, and NF-kB signaling. It is recently reported that TBK1 directly engages Akt survival signali
Autor:
Bethany Kaplan, Joseph M. Amann, Marcin Imielinski, Miguel A. Villalona, Leora Horn, Matthew Meyerson, Luiz H. Araujo, David P. Carbone, Heidi Greulich
Publikováno v:
Molecular Cancer Therapeutics. 12:C139-C139
Targeted cancer therapies often induce "outlier" responses in molecularly defined patient subsets. One patient with advanced-stage lung adenocarcinoma who was treated with sorafenib demonstrated a near-complete clinical and radiographic remission for
Autor:
Chang-Soo Yun, Hee Jung Jung, Sung Yun Cho, Kwangho Lee, Jae D. Ha, Pilho Kim, Chi Hoon Park, Chong Ock Lee, Hyoung Rae Kim
Publikováno v:
Molecular Cancer Therapeutics. 12:A287-A287
c-Met recepter tyrosine kinase (RTK) and its ligand, hepatocyte growth factor (HGF), have been reported to be involved in tumorigenesis and metastatic progression. Also, aberrant c-Met signaling has been reported in a wide variety of cancers such as
Autor:
Ernest Medina, Gavin S. Choy, Francis J. Giles, Jennifer S. Carew, Steffan T. Nawrocki, Ronan T. Swords, Pietro Taverna, Kevin R. Kelly, Devalingam Mahalingam, David J. Bearss
Publikováno v:
Molecular Cancer Therapeutics. 8:B272-B272
The PIM kinases (PIM1, PIM2, and PIM3) are constitutively active serine/threonine kinases that promote tumorigenesis in mouse models and are associated with drug resistance. Upregulation of PIM kinase expression has been reported in many malignancies